NHS England chief executive Sir Jim Mackey has told the Parliamentary Health and Social Care Committee he will write to Palantir requiring it to share and clear with NHS England any future claims about the benefits of the Federated Data Platform, after the Office for Statistics Regulation (OSR) found that the organisation's own published figures could not establish that the platform caused the improvements attributed to it.
Mackey was giving evidence to the committee on 4 November alongside the Health Secretary, Yvette Cooper, and the Department of Health and Social Care's permanent secretary, Samantha Jones. Ben Coleman, the Labour MP for Chelsea and Fulham, put it to him that NHS England had cautioned against attributing improvements directly to the platform while Palantir's new UK senior vice president, Tom Watson, was publicly claiming that the changes were due to Palantir. Mackey said he would tell Palantir that it had to share and clear any benefits claimed in future, but added that although the company should share them, contractually this looked hard to enforce.
NHS England told the OSR that numerous FOI requests seeking detail on how FDP data was analysed had prompted it, in part, to expand the methods page of its uptake and benefits website on 6 June 2026. At the same time it added the sentence "We cannot therefore draw conclusions about cause and effect as other variables have not been controlled for" to every section where the published benefits rest on a before-and-after comparison of performance.
In July, health campaign group Foxglove reported on the basis of its own FOI responses that nearly a third of trusts using the platform were performing fewer procedures than before it went live, and wrote to the then Health Secretary questioning figures that ministers had used in Parliament.
The OSR, the regulatory arm of the UK Statistics Authority, examined the matter under its casework function and published a statement on 22 July. It said the caveat was welcome but understood why many users had read it as a significant change in how NHS England was communicating the platform's benefits. NHS England's FDP Benefits and Assurance team accepted that more could be done and committed to:
- adding the cause-and-effect caveat to the main page of the uptake and benefits site, alongside a distinction between counts of actions taken through FDP products and NHS England's own before-and-after calculations
- ensuring all public-facing communications label before-and-after comparisons as such and include clear information about causality
- preparing a publishing schedule for trust-level benefits data
- drawing attention to any changes in methods at the time they are made
- clarifying that FDP case studies are written by the organisations using the platform and are not authored or verified by NHS England
The OSR also said the role of statistical teams in informing the external outputs of NHS England and DHSC should be strengthened through closer working with media teams and ministerial private offices, and that it expected any figures cited by ministers or in official briefings about the platform to be communicated clearly and accurately. It said it would monitor future uses of FDP data.
Watson, the former deputy leader of the Labour Party, said in a statement on X in October that the OSR had pointed out there had not yet been a study controlling for factors such as staffing changes or industrial action, describing this as a fair note of caution. In the same period he repeated the figure of 137 trusts reporting benefits without the caveat, and in a video said Northampton General Hospital, University Hospitals of Derby and Burton and Chelsea and Westminster Hospital had all produced figures showing benefit from the platform.
The Guardian reported on 2 November that 29 trusts listed by NHS England as realising benefits had said in FOI responses obtained by the campaign group Medact that the platform was not live or that they were not using its applications. University Hospitals of North Midlands NHS Trust told a requester in July that the FDP was not live and that it did not intend to roll it out, as it did not appear to provide functionality beyond what the trust already had.
NHS England's uptake page states that the benefits count includes trusts using data analysis and submission tools for back-office activity, not only the operational products that support patient care. An NHS England spokesperson said the platform was universally available to trusts and integrated care boards, which could select individual tools depending on their needs, and that 137 trusts had reported benefits from the range of tools available.
The £330m contract with the Palantir-led consortium was awarded in November 2023 and runs to March 2027. Ministers must decide by December whether to extend it. NHS England appointed Imperial College Projects in February 2026 to carry out an independent evaluation, with the OSR noting that the Inpatients and OPTICA products, where the question of causality is most acute, would be prioritised.
The evaluation's findings are not expected before the extension decision. James Frith, the minister for health innovation, told the Science, Innovation and Technology Committee in October that publishing detail of the contract's exit plan would be likely to prejudice commercial interests.
